Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rapamycin for difficult-to-treat epilepsy in children with tuberous sclerosis complex
NL-OMON28870Active, not recruiting
- Sponsor
- Erasmus MC
- Start
- Sep 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of sirolimus in epilepsy and tuberous sclerosis complex (TSC) (2 arms), sponsored by Erasmus MC. Primary endpoint: Change in seizure frequency. Started Sep 2011; status: active, not recruiting.
02
Drugs
sirolimus
03
Conditions
epilepsytuberous sclerosis complex (TSC)
Beyond the preview
Go deeper on NL-OMON28870.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON28870.